Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Large Increase in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totaling 8,509,923 shares, an increase of 234.4% from the April 15th total of 2,544,706 shares. Based on an average daily trading volume, of 79,730,843 shares, the short-interest ratio is currently 0.1 days. Currently, 25.4% of the company’s stock are short sold.

Theriva Biologics Stock Down 2.7%

TOVX traded down $0.01 during trading hours on Thursday, hitting $0.32. 2,076,673 shares of the company’s stock were exchanged, compared to its average volume of 45,291,652. Theriva Biologics has a 12-month low of $0.16 and a 12-month high of $0.86. The firm has a 50 day moving average of $0.26 and a 200 day moving average of $0.24. The firm has a market cap of $10.83 million, a P/E ratio of -0.01 and a beta of 1.17. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group raised shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, According to MarketBeat, Theriva Biologics currently has an average rating of “Buy” and a consensus price target of $1.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP purchased a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent SEC filing. Institutional investors and hedge funds own 6.17% of the company’s stock.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.